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Objective: The analysis of clinical trials in delirium is typically complicated by treatment dropouts and by the
fact that even untreated individuals may have a good prognosis. These features of delirium trials warrant
special statistical attention; implications for each stage of a trial planning process are described.
Methods: Choice of outcome, patient sample, and data collection in delirium trials are discussed. Descriptions
are given, together with examples, of time-to-event, imputation-based, linear and nonlinear models for the
analysis of randomised controlled trials for delirium.
Results: Imputation allows evaluation of the plausibility of individual recovery trajectories, but some simple
imputations are found to be unsuitable for delirium research. Time-to-event and nonlinear models encourage
a global perspective on analysis, which is often preferable to cross-sectional end-of-trial assessments. It is
suggested that nonlinear random effects models for longitudinal trajectories are particularly suitable in a
delirium context.
Conclusion: It is hoped that the methods described, and nonlinear models in particular, will play a part in
convincing analyses of future delirium research.© 2012 Elsevier Inc. Open access under CC BY license.Introduction
The objective of the present paper is to consider some of the
statistical issues that arise during the conduct of randomised trials
in delirium. Delirium is a serious and complex neuropsychiatric
syndrome that can ﬂuctuate and improve irrespective of the treatment
given, which raises important statistical questions at each stage of a
scientiﬁc study. The principal focus herein is analysis and, in particular,
on the analytical challenges raised by the common problem of sample
attrition. This chosen emphasis is not because analysis is the most
important part of a clinical trial, but because it is here that there is
greatest potential for improvement over current practice.
Patients may drop out because of adverse reaction to treatment,
rapid deterioration of condition, relapse or recovery. Dropouts neces-
sarily lead to a loss of statistical power, but may also raise concerns
regarding the validity of conclusions drawn based on partially ob-
served data. For all of these reasons, it is important to think carefully
about statistical approaches to interpreting delirium trials. We have
communicated previously on this subject [1]; the goal of the present
paper is to expand further on statistical topics arising in delirium
research.
The approach is chronological, and the typical phases of a delirium
trial, from planning to analysis and trial reporting, are discussed in).
license.turn. Selected statistical methods are reviewed, along with their under-
lying assumptions and the implications for delirium research. Where
appropriate, ideas are illustrated from a historical randomised trial
that compared the effectiveness for delirium control of an active treat-
ment against placebo [2].
Throughout, attention is restricted to randomised trials, since the
most robust evidence for the treatment of delirium is based on the
thirteen randomised trials that have been conducted to date (Table 1).
Nevertheless, many of our remarks have relevance outside this speciﬁc
study design. As the body of evidence for the pharmacological treat-
ment of delirium grows, it is to be hoped that the sophistication of
statistical methods used will grow in parallel.
Methods
Choice of main outcome
The ﬁrst decision facing investigators in delirium contexts is the
selection of the main outcome of interest. In other words, what mea-
surements (or derived quantities) will be used to assess the effective-
ness of an intervention? This is necessarily a balancing act between
clinical relevance, ease of data collection and statistical convenience:
some outcomes, such as the results of psychiatric interviews, are
well-established predictors of longer-term patient prognosis but are
costly to collect or difﬁcult to analyse, while others may have only
short-term relevance but can be gathered and analysed more simply.
Table 1
Randomised trials for treatment of delirium. Principal statistical approaches used by
the authors are also indicated. n = sample size, d = dropouts
Study Drug n d Population Methods
Breitbart et al.
(1996) [15]
Haloperidol vs. 11 2 AIDS ANOVA
Chlorpromazine
vs.
13 2
Lorazepam 6 6
Han and Kim
(2004) [16]
Haloperidol vs. 14 2 Mixed medical–
surgical
ANOVA
Risperidone 14 2
Skrobik et al.
(2004) [17]
Haloperidol vs. 45 ? Medical and surgical
ITU
t-Test, ANOVA
Olanzapine 28 ?
Kim et al.
(2005) [18]
Haloperidol vs. 24 ? Medical, oncology
ITU
Time-to-event
Risperidone 18 ?
Lee et al.
(2005) [19]
Amisulpride vs. 20 4 Medical, ITU and
oncology
Time-to-event
Quetiapine 20 5
Hu et al.
(2006) [20]
Olanzapine vs. 74 1 Senile dementia t-Test
Haloperidol vs. 72 4
Control 29 18
Devlin et al.
(2010) [4]
Quetiapine vs. 18 0 Intensive care unit Time-to-event
Placebo 18 2
Tahir et al.
(2010) [2]
Quetiapine vs. 21 5 General hospital Nonlinear
modelPlacebo 21 8
Girard et al.
(2010) [21]
Haloperidol vs. 35 2 Intensive care unit Time-to-event,
GEEZiprasidone vs. 32 2
placebo 36 2
Kim et al.
(2010) [22]
Risperidone vs. 17 5 General hospital LOCF,
time-to-eventOlanzapine 15 7
van Eijk et al.
(2010) [8]
Rivastigmine
vs.
55 19 Intensive care unit Time-to-event
Placebo 54 15
Overshott et al.
(2010) [23]
Rivastigmine
vs.
8 1 Medical wards t-Test
Placebo 7 4
Grover et al.
(2011) [24]
Haloperidol vs. 26 6 General hospital ANOVA
Olanzapine vs. 26 3
Risperidone 22 1
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we consider here only broad classes of endpoint, divided based on
their analytical properties.
End-of-trial outcomes are often employed in delirium research.
Use of such measures is usually aimed at comparing medium-term
prognosis between different treatment groups. This is clearly impor-
tant from a patient perspective, and may provide the best available
estimate of longer-term health status. However, end-of-trial psychi-
atric assessments are not always a natural choice. The most obvious
reason for this is that, for some patients, end-of-trial psychiatric as-
sessments can be suspect or unavailable: patients may discontinue
treatment (treatment dropouts, see [3]), data collection may be dis-
continued (analysis dropouts, see [3]) and, of course, patients may
die. Certain dichotomous end-of-trial outcomes, such as recovery or
discharge, can be assigned to the subset of patients who die: clearly,
death contraindicates both these positive outcomes. However, other
reasons for dropout may be less neatly tied to recovery from delirium.
A further, more fundamental, reason that standard end-of-trial out-
comes are often inappropriate in delirium trials is that an untreated
control group also has the potential to improve and recover. Even
with no dropouts, then, an end-of-trial comparison of treatment groups
may fail to capture the true effects of treatment, whichmight instead be
seen in the speed or trajectory of recovery, not just a single numeric
value at the end of a trial.
Similar endpoints carrying somewhat more information are time-
to-resolution and time-to-discharge. Unlike dichotomous endpoints,
time-to-event outcomes cannot usually be inferred in a simplemanner,
so we return later to the special analytical tools that are used to handle
this kind of censored data.When treatment group differences are small,
time-to-event outcomes are arguably less relevant from a patient per-
spective than end-of-trial outcomes. However, their importance for
healthcare providers is potentially substantial; a small improvementin individual time-to-discharge can rapidly accumulate ﬁnancial and
operational beneﬁts, when considered across an organisation.
There are at least two factors that motivate us to consider main
outcomes other than those described above. Firstly, in order to con-
duct a time-to-resolution analysis, delirium resolution needs to be
precisely deﬁned. Devlin et al. [4], for instance, acknowledged that
no standard deﬁnition of resolution exists, but took the reasonable
decision to dichotomise a delirium rating scale. This decision is, how-
ever, unavoidably subjective, and analyses that do not require setting
arbitrary cutpoints may be preferable. Some of the challenges in-
volved in deﬁning delirium resolution are pre-existing cognitive def-
icits (particularly in those with dementia), the impact of physical
illnesses on cognitive abilities, and the high rate of mortality associat-
ed with underlying physical pathology.
Even if cutpoints are deﬁned based on external criteria, such as those
for the DRS-R-98 score given in [5], the fact that delirium rating scores
can (and do) ﬂuctuate above and below any subjective cutpoint calls
into question the usefulness of dichotomised scales. Another possibility,
then, is to analyse not just an end-of-trial delirium rating score but the
set of all scores associatedwith a patient. Analysis of longitudinal trajec-
tories again requires specialised tools, which we describe later, for un-
derstanding the effects of treatment.
Design
There is another reason to avoid dichotomisation, if possible.
Trzepacz et al. argue that difﬁculty in enrolling patients in delirium
trials will mean that sample sizes tend to be small [6]. For this reason
it is desirable to maximise the information contribution of every pa-
tient. Dichotomised scores clearly provide less detail for analysis
than the score itself, and the longitudinal trajectory carries more in-
formation than either time-to-event or single-outcome data.
Of course, multi-centre trials can overcome some of the difﬁculties
in recruiting sufﬁcient patients to conduct delirium research. This is
especially advantageous if a study of subgroups is desired; risk factors
vary widely between patients, and stratiﬁed randomisation may help
to understand the effects of treatment; for instance, when delirium is
brought on by pneumonia. Nevertheless, it seems clear to us, even
given a large sample, that we should prefer efﬁcient uses of whatever
information is gathered. Studies using longitudinal trajectories as
the main outcome will almost always have greater power than end-
of-trial based analyses.
If longitudinal trajectories are to be the main outcome of interest,
then it is worth giving special consideration to the planned observa-
tion schedule. Typically, measurements are collected more frequently
towards the start of a trial, with lengthening intervals between waves
of data collection as the trial progresses. However, our recommenda-
tion is to have at least two periods of high-frequency observation; this
provides useful information in understanding the variation in trajec-
tories of both early and late dropouts from trials, which often are
qualitatively different one from another. Among patients treated in
a trial setting, early dropouts are often largely composed of acute
cases, while later dropouts are more often due to transfer or recovery.
Design, like the main outcome, cannot usefully be chosen in isola-
tion, andmust be conducted with reference to the proposed statistical
analysis, of which more discussion later.
Data collection
When attrition is a real possibility, an important aspect of data col-
lection is that it should not be limited to the main outcome. Whenev-
er all or part of the main outcome data may be missing, it is useful to
know as much as possible about the patient before, and after, the mis-
sed measurement. This auxiliary information may take the form of
simpler indicators of delirium status, prose descriptions of the reason
that the patient or clinician decided to terminate treatment or data
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Fig. 1. Probability of delirium. The smooth curves are model-based estimates, with the
solid line representing the placebo group and the dashed line representing the active
treatment group. Lighter shades show their Kaplan–Meier equivalents.
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Any or all of these may contribute to a better appraisal of the plausi-
bility, or otherwise, of the competing assumptions underlying the
different procedures that can accommodate partial outcome data, to
which we now turn.
Analysis
Although Adamis has outlined several statistical methods that
may be useful for the analysis of treatment trials [7], only three recent
studies considered trial dropouts in detail as part of the statistical
analysis [2,4,8]. In this section, we describe four techniques that,
in quite different ways, overcome some of the limitations of data
truncated by dropout or death.
As an illustration of the practical application of these statistical ap-
proaches, we present results from a trial of an active pharmacological
agent for the treatment of delirium. Details on the trial itself can be
found elsewhere [2]; brieﬂy, 42 patients were randomised to one of
two treatment groups, and the Delirium Rating Scale Revised 98
(DRS-R-98) was used as the primary outcome measure [5]. We
focus here on the DRS-R-98 severity scores.
Our selection of four analytical approaches is by no means exhaus-
tive. The statistical literature surrounding generic missing data, and
dropout in particular, continues to grow apace [9]. One important
consensus amongmissing data specialists, though, is that it is prudent
to consider how results might change if different statistical assump-
tions were adopted. This sensitivity analysis can be conducted formal-
ly, by varying the inputs to a statistical model, or informally, simply
by employing multiple analytical approaches. We illustrate the latter
approach using the historical trial data.
In commending multiple analyses as a means of exploring sensi-
tivity to assumptions about dropouts, we should be clear that we
are not proposing a post hoc search for a desirable ﬁnding. If more
than one analysis is conducted then more than one analysis should
be reported. If their results are broadly similar, we gain extra conﬁ-
dence in our reporting; if they differ substantively, then the role
of the auxiliary information gathered alongside the main outcome
becomes even more important in selecting between competing tech-
niques, if indeed any are appropriate.
Generally, we argue for a ﬂexible approach to the analysis of trial
data. While there are evidently some aspects of an analysis plan
that can and should be speciﬁed pre-trial (the main outcome and pro-
posed subgroup analyses, for instance), there are also components of
a statistical model that ought to be inferred from the data. In particu-
lar, it is difﬁcult and unnecessary to prespecify the likely form of over-
all and individual longitudinal trajectories, which can instead be
explored by a data scientist with a view to optimising the ﬁt of the
model to the data.
Time-to-event analysis
Devlin et al. report on a pilot placebo-controlled trial in an inten-
sive care context [4], and use time-to-resolution from delirium as
their main outcome. In common with almost all time-to-event analy-
ses, not everyone experiences the event (in this case, resolution), so
the approach of Devlin et al. admits study dropouts in a very natural
fashion: they are treated as censored observations, individuals for
whom we do not know the resolution time. Instead, we know only
that their resolution time is greater than the time they were under
observation, before dropping out. The central assumption underlying
time-to-event analyses is that the dropouts must not be systematically
different from those whose delirium is resolved while under observa-
tion. This supposition would be violated if (say) healthier individuals
discharged themselves before delirium resolution could be conclusively
determined. If the assumption of representative censoring is thought
to hold, then the partially observed patients may still contribute to the
statistical analysis until the point of censoring. Table 1 illustrates thattime-to-event analyses are not uncommon in publications concerned
with delirium, though the care with which these are undertaken varies
from study to study.
To illustrate the approach, we carried out a time-to-resolution
analysis of historical trial data [2]. Devlin et al. used a log-rank test
based on censored resolution information to compare active treat-
ment with placebo groups; we prefer to use a (so-called) accelerated
failure time (AFT) regression model to estimate the difference in rates
of recovery between the two groups [10] (p44). Our feeling is that a
difference in recovery rates is a useful, interpretable quantity, having
relevance for both clinicians and patients.
To carry out a time-to-resolution analysis, we must (of course)
ﬁrst deﬁne resolution of an episode of delirium. Here we use the se-
verity score of the DRS-R-98, and deﬁne resolution as the ﬁrst mea-
surement less than 13. Using this deﬁnition and an AFT model, we
estimate that the active treatment group recovered 42.9% more
quickly than the placebo group (95% CI −3.5% to 111.6%, p-value
.07) over the course of the trial. In other words, the proportion recov-
ered in the active treatment group at day 7 would not be expected to
be matched by that in the control group until day 10 (10≈1.429×7).
Fig. 1 shows the model-based and non-parametric Kaplan–Meier esti-
mates of the probability of delirium over the ﬁrst 10 days of the trial.
As we have already said, many other deﬁnitions of recovery are
possible, including those that combine multiple scales or subscales.
We therefore examined several other possibilities, details and speciﬁc
results which are available from the authors. Unfortunately, the esti-
mated difference in recovery rates is highly sensitive to choice of def-
inition of resolution. A substantial majority of analyses favour the
active treatment, some very strongly so, but this is not uniformly
true. In our view, this is a disadvantage of the time-to-resolution ap-
proach: at the very least, it depends on a subjective decision about
what constitutes recovery, and is potentially wasteful of valuable in-
formation. In the absence of an established deﬁnition of resolution
of delirium, there is the possibility of failing to recognise a real im-
provement in resolution time or, conversely, detecting an apparent,
but spurious, effect of treatment. A further disadvantage of this type
of analysis is that if, as in this case, DRS-R-98 is only measured rela-
tively infrequently, we may not be able to accurately specify the
time of resolution. If, for instance, an individual's severity score is
23 at day 10 but 12 at day 30, we lack a clear idea of when ‘recovery’
took place. This is known generically as interval censoring, and usual-
ly adds to the complexity of a time-to-resolution analysis.
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Another approach tomissing data problems involves the analyst ﬁll-
ing in the unrecorded values, known generically as imputation. Imputa-
tion can be a useful procedure, since the plausibility of the imputed
trajectories can be explicitly examined, and since standard statistical
methods can be brought to bear on the resulting ‘complete’ data. Clear-
ly, the success of such a strategy depends strongly on the skill of the an-
alyst in reconstructing what might otherwise have happened, had the
patient not dropped out. By no means is this straightforward, and gen-
eral prescriptions for meaningful imputations are difﬁcult. Here, we re-
strict ourselves to a cautionary note about two variants of a commonly-
employed imputation strategy, and make two suggestions about how
these simple imputations might be improved upon in the delirium
context.
As their names suggest, Baseline Observation Carried Forward
(BOCF) and Last Observation Carried Forward (LOCF) ﬁll in the missing
valueswith, respectively, the initial ormost recently recordedmeasure-
ment. The obvious advantage of B/LOCF is simplicity of implementation;
however, it is important to realise that simplicity of interpretation does
not necessarily follow. Criticisms of these imputation mechanisms
abound [7,9], but it is particularly easy to see why they will fail to
have much relevance in trials of delirium. Recovery is expected in
most delirium patients, but these imputations suggest instead that the
most recently observed value (or, worse, the initial measurement)
will be maintained indeﬁnitely. This is quite implausible, and hence
highly likely to introduce bias into any analyses conducted on the
basis of the imputed data.
To impute measurements that more adequately reﬂect a general
trend towards improved psychiatric condition, one possibility is to
ﬁnd the midpoint between the most recent patient-speciﬁc observa-
tion and the mean of all available (genuine, unimputed) observations
at the measurement time of interest. This affords the analyst a com-
promise between acknowledging, on the one hand, that between-
patient variability is likely to be high, and on the other that patients
tend to follow similar recovery trajectories. We call this approach “re-
alistic mean” imputation, and proceed to contrast it with the BOCF
and LOCF imputations in the simple example shown in Table 2. A re-
ﬁnement of this idea would impute a recovery trajectory among those
who are analysis dropouts but a worsening trajectory among those
who go on to die; we do not pursue this idea further here.
The BOCF imputation at day 4 (20) is manifestly unlikely, while
the LOCF imputation (14) is scarcely better. Imputation of the com-
pleter mean (8) is another possibility, but fails to recognise that this
individual is making a slower-than-average recovery. At least in this
instance, the realistic mean imputation (11=(14+8)/2) seems to
us to earn its name: it may not be real, but it is realistic. Further miss-
ing values can be imputed sequentially, taking the average of the
most recent imputation and the current completer mean. A related
idea, called Last Residual Carried Forward (LRCF) ﬁnds the most recent
subject-speciﬁc deviation from the completer mean (2=14−12) and
then adds this to the completer mean at the relevant point in time
(10=8+2) [9].
Two features are common to all of the imputations discussed so far:
all are single, deterministic imputations and all are nonparametric (that
is, no formal statisticalmodel is used in their computation). Of these, the
ﬁrst is probably the greaterweakness, since failure to convey the uncer-
tainty surrounding our imputations in turn risks overstating the preci-
sion of our conclusions. Multiple imputation, then, adds a stochastic
(that is, random) component to whatever procedure is used to ﬁll inTable 2
Example individual and average trajectories for DRS-R-98 severity score
Day 1 Day 2 Day 3 Day 4
Patient raw data 20 17 14 ?
Completer mean 22 16 12 8the missing values, and conclusions are averaged across several ver-
sions of the in-ﬁlled data. There exist simple rules for quantifying the
uncertainty inherent in multiply-imputed analyses [11].
In principle, imputation (single or multiple) allows the analyst to
ﬁt whatever statistical model they desire, since the data are explicitly
completed. We reiterate that the usefulness of these inferences is di-
rectly related to the quality of the imputation procedure. We illus-
trate the foregoing four imputations here, in order to directly
examine the plausibility of imputed recovery trajectories. Fig. 2
shows the resulting imputations for all 13 individuals for whom
some data were missing. Imputed data are shown in bold, while ob-
served trajectories (for all 42 participants) appear in light grey. Impu-
tation was blinded to treatment, so the imputations that require
knowledge of the completer mean – that is, all except LOCF – were
based upon averages arising from subjects in both treatment arms.
It is clear that imputation of the completer mean fails to adequately
capture the variability in the proﬁles, while LOCF does not reﬂect
the overall trend towards recovery. Both realistic mean and LRCF im-
putations are more plausible, but it is our belief that the end-of-study
stability of the realistic mean imputations is desirable. Since our goal
in this section is purely illustrative, we refrain from adding a random
component and making multiple imputations. Given these imputa-
tions, we can compare the average levels of the DRS-R-98 severity
score between the two treatment groups. Irrespective of the imputa-
tion used, very little evidence of any end-of-trial treatment differ-
ences was uncovered: none of the imputations showed a signiﬁcant
difference between mean levels at day 30. However, as Fig. 3 illus-
trates, there was some suggestion of a difference in mean levels ear-
lier in the trial. In particular, at day 3 and across all imputations, the
mean of the active treatment group was signiﬁcantly lower than the
mean of the placebo group. This consistency is unsurprising, since
only three observations were missing at this point in time (see
Fig. 2). As Table 3 illustrates, the estimated differences in mean levels
at day 3 ranged from−4.90 (LOCF) to−4.03 (completer mean), with
the realistic mean and LRCT imputations intermediate to these values.
Recall from our discussion of multiple imputation that single imputa-
tion (as we have done here) is likely to overstate somewhat the
precision of our ﬁndings; nevertheless, the magnitudes reported in
Table 3 would remain unaffected.
In isolation, signiﬁcant differences at day 3 but nonsigniﬁcant dif-
ferences at day 30 make it tempting to conclude that the effect of the
pharmacological agent must therefore be limited to the early portion
of the trial, but (as we shall see) other interpretations are possible. A
potential disadvantage of realistic mean imputations is that the im-
puted recovery trajectories will necessarily stabilise at ‘true’ recovery,
whatever that may look like; this lack of variation may be unrealistic.
A corresponding disadvantage of LRCF imputation is that it is quite
possible to impute measurements that do not respect the limits of
the scale: negative DRS-R-98 severity scores, for example. Despite
the fact that both realistic mean and LRCF are (in this sense) some-
what naïve imputations, they both represent a simple and substantial
improvement over the manifestly inappropriate BOCF and LOCF
options. More sophisticated options exist (for example, [12]), but
typically require consultation with a statistician.
Linear models
Because generating believable imputations is a difﬁcult business,
some practitioners prefer not to directly impute, but instead rely on
more generic assumptions concerning the nature of the mechanism
that leads to subjects dropping out of a trial. It is to this kind of
approach that we now turn.
One prominent type of statistical inference depends on calculating
the values of model parameters that maximise a mathematical func-
tion called the likelihood. There exist widely-known conditions on
the dropout mechanism under which likelihood-based procedures re-
tain the desirable property that conclusions are unbiased in large
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Fig. 2. Imputation plots. Imputed trajectories are shown as dark lines, with observed trajectories in a lighter shade.
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technical but, roughly, provided patients drop out (or are removed
from a trial by attending physicians) on the basis of observed mea-
surements only, then the dropout is said to be ‘missing at random’
and likelihood inferences are valid. Put more informally, data are
missing at random if whatever caused the patient to drop out does
not depend on the missing outcome itself. In this sense, missingness
at random is similar to the representative censoring assumption
used in time-to-event analyses.
The missing at random supposition is always hard to verify empir-
ically, but we comment brieﬂy on its plausibility in our historical data.
Of the 42 individuals randomised, 13 dropped out of the study before
day 30. Of these 13 dropouts, 4 died; mortality raises challenging
philosophical questions regarding the precise scientiﬁc objective
[14]. One patient left the study before beginning treatment. Mis-
singness due to non-compliance (in this case, 3 patients) or physician
intervention (3 patients) can often be assumed to be (approximately)
at random, because individual decisions are usually taken on the basis
of information available prior to dropping out. The remaining 2 pa-
tients experienced adverse events; for them, the assumption of mis-
singness at random is less plausible, since presumably these events
may also have been reﬂected in the (unobserved) DRS-R-98 severity
scores. With this qualiﬁcation, we proceed with the analysis under
the assumption of random missingness.
Crucially, if dropout is missing at random, then no formal imputa-
tion of missing values is required. However, the statistical model
employed must be able to accommodate sequences of observations
that vary in length between individuals. One such is the so-called
‘random effects’ or ‘mixed effects’ model, sometimes known more
generically as a repeated measures analysis. Random effects models
allow for the fact that the measurements making up an individual'slongitudinal trajectory are correlated: if a patient scores highly on a
delirium rating scale at baseline, they are more likely to continue to
score highly throughout. Random effects models are particularly
well suited to characterising variation between individuals, allowing
some patients to be higher-than-average or faster-than-average re-
sponders throughout the course of a trial (and conversely). The sim-
plest form of random effects model is a variant of linear regression;
linear mixed effects models offer many advantages, including stable
estimation and straightforward relationships between population av-
erages and individual responses. Maximum likelihood techniques can
be used to ﬁt mixed effects models, a useful approach provided that
dropout can be assumed to be missing at random.
In the historical trial data, we can allow for different mean values
for both treatment groups and each observation occasion, and ac-
count for correlation within a patient's observations by introducing
a random linear trajectory, the variance of which we estimate. The
overall mean trajectories are very similar to those shown in Fig. 3.
Rather than report individual coefﬁcients, we focus on a global mea-
sure of improvement: the average difference between treatment
groups, across all measurement occasions. On average, the active
treatment group was 2.05 points lower on the DRS-R-98 severity
scale (95% CI −0.37 to 4.47, p-value .097), demonstrating weak evi-
dence for an effect on delirium severity across the whole period of
the trial. However, since this comparison gives equal weight to
every observation point, it will tend to underestimate treatment
effects on a self-limiting condition such as delirium.
Nonlinear models
Recall that the two main advantages of the time-to-resolution ap-
proach to analysis of delirium trials are the ease with which data from
subjects who drop out may be included, and the natural way in which
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Fig. 3. Group mean plots. The placebo group is shown as a solid line, with the active treatment group shown as a dashed line.
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groups. Linear mixed effects models share the ﬁrst advantage, but
do not provide a natural framework for comparing speed of recovery.
For this, we must turn to nonlinear models.
Nonlinear models abandon the restrictive assumption that param-
eters relate in a simple way to the measured responses, at the cost of
more arduous estimation and added complexity in mathematical in-
terpretation. However, they offer one enormous advantage: model
parameters can be (and usually are) quantities of direct scientiﬁc in-
terest, such as a difference in recovery speeds between two treatment
groups. Consequently, although more troublesome from a statistical
perspective, nonlinear models are often more appealing from a scien-
tiﬁc point of view. Whether or not this advantage is sufﬁcient to out-
weigh the disadvantages inherent to nonlinear modelling is inevitably
application-speciﬁc.Table 3
Imputed mean trajectories. Within each imputation type, the mean of the placebo
group (Plac.) is shown on the left, with the mean of the active treatment group (Act.)
on the right
Day Observed mean LOCF Realistic mean LRCF
Plac. Act. Plac. Act. Plac. Act. Plac. Act.
1 18.905 19.190 18.905 19.190 18.905 19.190 18.905 19.190
2 14.695 12.476 15.286 12.476 14.990 12.476 15.026 12.476
3 13.650 9.632 14.333 9.429 13.844 9.531 13.981 9.243
4 8.721 8.036 10.286 8.143 9.258 8.140 9.467 7.647
7 8.899 8.045 10.190 8.143 9.031 8.093 9.390 7.656
10 8.501 5.263 10.810 6.952 9.011 6.083 9.701 6.163
30 5.227 4.706 10.571 6.857 7.000 5.347 8.825 5.611The historical trial data were gathered with a simplistic cross-
sectional main outcome measure in mind. However, since longitudi-
nal data were gathered, we felt strongly that we ought to (a) make
use of all available data; (b) avoid subjective dichotomisation; (c) ac-
commodate incomplete data records; and (d) directly compare the
speed of recovery of our two treatment groups, leading to our ulti-
mate choice to present both the prespeciﬁed analysis and to ﬁt
nonlinear mixed effects models [2]. Like the time-to-resolution anal-
ysis, it aims to estimate the difference in recovery rates between the
two treatment groups; like the linear mixed model, it is based on a
‘missing at random’ assumption and does not explicitly impute any
data. The model we used incorporated terms quantifying the rate of
progression towards recovery in the placebo group, the acceleration
in recovery in the active treatment group, a common mean at the
start of the trial and a shared long-term prognosis, together with
between-patient and within-patient sources of variation.
An extreme observation in the placebo group at day 10 has a no-
ticeable effect on the rate difference (in favour of the active treat-
ment). Deleting this single observation in order to make our
ﬁndings more robust, the difference in recovery rate is estimated to
be 0.827 (p-value .026). This ﬁgure (82.7%) is directly comparable
to the 42.9% improvement in the time-to-resolution analysis, and in
particular the mean level in the active treatment group at day 4
would not be expected to be reached in the placebo group until day
7 (7≈1.827×4). However, the difference is perhaps most easily
interpreted with reference to Fig. 4, showing the model-based esti-
mates of the mean recovery trajectories in the two treatment groups.
Notice how the mean trajectories estimated from the nonlinear
model capture many of the features discussed throughout this
paper: the largest difference at any single point in time is observed
around day 3; most of the impact of the active treatment is seen
203D. Farewell et al. / Journal of Psychosomatic Research 73 (2012) 197–204before day 10; by day 30, the mean of both treatment groups has sta-
bilised around 7 points on the DRS-R-98 severity scale. Both between
and within patients, there is substantial variation around these mean
trajectories, and nodata have been imputed. Nonetheless, by employing
a statistical model that is well-suited to the features of delirium trials
we have discussed, we are able to better explore the clinical implica-
tions of introducing the pharmacological agent on the rate of recovery
on the DRS-R-98 severity scale.
Sensitivity analysis
To our knowledge, this is the only comparative analysis of trial
data in a delirium setting. Different statistical approaches highlight
different aspects of the data: imputation averages and linear models
emphasise differences in group means, while the time-to-event and
nonlinear models focus on progression towards recovery. Reassuring-
ly, there is a large degree of consistency between the analyses reported
here. Taken together, the quantitative results seem to us to paint a con-
vincing qualitative picture that – at least in this instance – the active
treatment has had a beneﬁcial effect on the treated group.
Discussion
In this paper, we have considered several statistical points of view
on the same scientiﬁc problem: estimating the effect of treatment in
delirium trials, especially when some observations may be missing.
As will be evident from the foregoing illustrative analyses, our recom-
mendations are based not only on successes, but also on the mistakes
that we have made, and learned from, in our own trial work.
We have chosen to illustrate the statistical methods that we con-
sider to be most applicable to delirium trials. There are, of course,
many other possibilities, ranging from slight variations on these
themes to entirely different perspectives. More broadly, then, our
view is that common features of delirium studies, such as small sam-
ple sizes, sample attrition and spontaneous recovery mean that tech-
niques are likely to be preferred if they make efﬁcient use of available
data and, more speciﬁcally, take a global (as opposed to end-of-trial)
perspective. This neatly summarises our recommendations to those
carrying out delirium research: design, recording and analysis of trialsday
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Fig. 4. Nonlinear model trajectories. The estimated placebo group mean is shown as a
solid line, with the estimated active treatment group mean shown as a dashed line.should maintain a global view of the progression of each patient, from
the point of recruitment to their ultimate death or discharge and,
hopefully, recovery.
Neither have we considered in detail all the statistical issues that
arise in delirium trials. For instance, a typical efﬁcacy trial might con-
sider several possible outcome measures, and questions of multiple
testing then surface. Also, all the approaches we have discussed rely
on an assumption of randommissingness [13] or similar; this is a lim-
itation, and remains an active area of statistical research. Much gener-
ic advice is available, but we also counsel early consultation with a
professional statistician, who can advise on the speciﬁc problems
that arise in delirium trials, and offer direction on selection and use
of an appropriate model.
Given that the body of reliable empirical evidence concerning the
treatment of delirium is sparse, it is unfortunate that detailed consid-
eration of analytical aspects of delirium trials is also rare. Ultimately,
it can be hoped that sufﬁcient data will emerge to swamp the effects
of less suitable mathematical models, but in the present state of fairly
limited knowledge (particularly about longer-term outcomes), con-
vincing analyses will be needed in order to inﬂuence professional
practice. It is our hope that the methods we have described will
play a part in convincing analyses of future delirium research.
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